Scientists test 'Double Punch' drug combo for Tough-to-Treat stomach cancers
NCT ID NCT06364410
Summary
This early-stage study is testing the safety and best dose of a new two-drug combination for people with advanced cancers that have a specific marker called HER2. The trial focuses on stomach and gastroesophageal junction cancers that have spread or cannot be removed by surgery, and also includes other solid tumors. The goal is to see if combining an existing targeted cancer drug with a new experimental pill is safe and might work better than the single drug alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.